MedTrace Logo

Remimazolam Sedation for Nerve Blocks

NCT05415202 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-09-28

No results posted yet for this study

Summary

Observational study recording sedation and safety of patients undergoing remimazolam sedation for peripheral nerve blocks.

Objectives:

To explore the safety and efficacy of remimazolam for neuraxial procedures and peripheral nerve pre-blocks and re-blocks.

Patients undergoing epidurals, fascial plane blocks, and peripheral nerve blocks will receive remimazolam for sedation.

Specific outcomes to assess include: depth of sedation, length of sedation, presence of apnea, presence of nausea/vomiting/other side effects, if the sedation was sufficient for the procedure.

Assessment methods:

MOAAS - Modified Observer's Assessment of Alertness and Sedation score Subjective patient report Vital signs Time for recovery Side effects

Hypothesis:

Remimazolam provides short-acting, adequate and safe sedation for peripheral nerve blocks in the ambulatory setting.

Conditions

  • Procedural Anxiety
  • Procedural Pain

Interventions

DRUG

Remimazolam 20 MG [Byfavo]

Remimazolam will be administered for sedation and efficacy and safety will be recorded

Sponsors & Collaborators

Principal Investigators

  • Jacob Brandenburg, MD · University of Utah

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-06
Primary Completion
2022-08-01
Completion
2022-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05415202 on ClinicalTrials.gov